Is Indiana Drug Policy at a Turning Point?

Indiana has long held its ground on drug policy, but that resolve is now wavering. Cannabis regulation in Indiana faces its biggest test yet. In a March 2026 fireside chat, Governor Mike Braun described himself as “kind of agnostic” on medical marijuana, noting that four neighbouring states have already legalised either medical or recreational cannabis. His suggestion that Indiana will “probably have to address it” has alarmed health advocates, former law enforcement officials, and public safety experts across the Midwest.

For those who have spent careers confronting drug misuse, agnosticism is not a governing position. It is an open door.

Peer Pressure Is a Poor Foundation for Indiana Drug Policy

Indiana does not need to follow its neighbours. That argument builds Indiana drug policy on peer pressure, not evidence. Ohio, Michigan, and Illinois moved in a particular direction. That does not obligate Indiana to do the same. States that legalised early ran an uncontrolled experiment on their own populations, and the results have not been encouraging.

Emergency department visits linked to cannabis surged in legalised states. A report from the American Journal of Preventive Medicine found cannabis-related emergency visits rose by 54% in states that legalised recreationally over a five-year period. Poison control calls involving children climbed too. Black market cannabis thrived alongside legal dispensaries rather than disappearing. Legalisation did not eliminate unregulated supply. It normalised the product while illicit growers and cartels simply adapted.

Following the crowd is not leadership. It is abdication.

Today’s Cannabis Is Not What People Remember

The public’s outdated picture of marijuana is one of the biggest obstacles facing sound cannabis regulation in Indiana. The drug in circulation today bears little resemblance to what existed decades ago. According to High Intensity Drug Traffic Areas (HIDTA) reports from across the Midwest, average THC concentrations have soared from under 4% in the 1990s to between 15% and 25% or higher in modern strains and concentrates.

This hyper-potent cannabis carries sharply elevated risks. Roughly one in ten users develops cannabis use disorder. For those who start before age 18, that figure rises to one in six. Researchers have linked high-potency cannabis to increased risks of psychosis and schizophrenia, particularly among young males. Clinical findings in peer-reviewed literature and federal health data consistently back that up.

Indiana drug policy cannot afford to be shaped by yesterday’s assumptions about a drug that has fundamentally changed. Indiana’s young people deserve protection from those risks, not exposure to them because a neighbouring state decided the tax revenue was worth it.

The Medical Marijuana Argument Has Already Failed Its Own Test

Proponents of loosening cannabis regulation in Indiana lean on the medical argument as their most palatable entry point. Legalise it for patients, they say, and harm stays contained. Compassion is the framing. But the evidence tells a harder story.

Early research suggested that states with medical marijuana laws recorded a reduction in opioid overdose deaths. Legalisation advocates treated that finding as a breakthrough. Subsequent, more comprehensive analyses reversed the conclusion entirely. Stanford University researchers found that medical marijuana states saw no meaningful reduction in opioid deaths and, in some analyses, recorded an increase. Cannabis did not replace opioids. In many cases it became an additional substance alongside them.

The medical route often works as the gateway to full recreational legalisation. Medical access arrives first. Perceived risk falls. Youth use climbs. Within a few years, the push for full legalisation follows. That pattern has repeated across multiple states, and Indiana drug policy needs to recognise it for what it is.

For genuinely therapeutic needs, a proper scientific route already exists. The US Food and Drug Administration approved THC-derived medications including dronabinol and nabilone for specific conditions such as chemotherapy-induced nausea and AIDS-related appetite loss. Every other medicine must meet those same clinical standards. The claim that patients lack legal access to cannabis-based treatment does not hold up.

What the Evidence Says About Legalisation in Other States

Indiana drug policy must reckon with what has actually happened where legalisation went ahead. The case against it does not rest on nostalgia or moral panic. It rests on documented outcomes.

Since legalisation across various US states, public health officials recorded consistent patterns. One in ten adults who use cannabis regularly develops use disorder. Among adolescents who begin before 18, that risk rises to one in six. A 2023 review in The Lancet Psychiatry found that daily cannabis users face a fivefold higher risk of psychosis compared with non-users. Roadside impairment has become a growing problem for law enforcement, with no reliable breathalyser equivalent in widespread use. Youth use has not fallen in legalised states, despite promises that regulated markets would keep cannabis away from children. Black market cannabis continues operating in every legalised state, undercutting legal prices and bypassing age limits.

None of those outcomes support the case for loosening cannabis regulation in Indiana.

Indiana Deserves Clarity, Not a Governor on the Fence

Governor Braun’s “kind of agnostic” framing may feel politically safe. It is not governing. Sound Indiana drug policy depends on clarity, not ambiguity. Public health, children’s developing brains, and the long-term safety of Indiana communities all require a leader who takes a firm, informed position. Residents deserve to know where their elected governor actually stands.

Former Indiana Attorney General Steve Carter spent years fighting drug misuse and opposing cannabis legalisation in any form. His position is straightforward: leadership requires clarity on a question that will shape a state’s health and safety for generations.

Indiana resisted the push to legalise while neighbouring states moved the other way. That restraint has not held the state back. It has given Indiana a clear view of what happens when policy chases trend rather than evidence, and that view is not a flattering one for the states that moved first.

Indiana Drug Policy Must Be Led by Evidence, Not Trend

Every generation of policymakers faces pressure to follow trends rather than evidence. The cannabis legalisation movement shaped the cultural narrative well. It framed opponents as out of touch and legalisation as simple common sense. But Indiana drug policy must answer to data, not to cultural momentum.

High-potency cannabis carries well-documented risks. Medical marijuana did not solve the opioid crisis. Black markets persist after legalisation. Youth use does not fall. States that moved forward with legalisation found new and complicated public health problems, not improvements.

Indiana still has the chance most states no longer have. Study what went wrong elsewhere. Look at the addiction rates, the emergency admissions, the failed promises. Then choose a different path. That choice needs a governor willing to say clearly where he stands. Hoosiers are watching.

Source: dbrecoveryresources